Meeting
2021 ASCO Annual Meeting
PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.
Authors
Margarita Majem
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Margarita Majem , Manuel Cobo , Dolores Isla , Diego Marquez-Medina Jr., Delvys Rodriguez-Abreu , Joaquín Casal Rubio , Teresa Moran Bueno , Reyes Bernabe Caro , Diego Perez Parente , Pedro Ruiz Gracia , Marta Marina Arroyo , Luis G. Paz-Ares
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9076)
DOI
10.1200/JCO.2021.39.15_suppl.9076
Abstract #
9076
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.
First Author: Rita Migliorino
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
Poster
2018 ASCO Annual Meeting
Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial.
First Author: Eve Maubec
